Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus

NCT02533453 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02533453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
January 28, 2016
Completion date
December 7, 2016
Enrollment
110 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus